Jeff Michalski, MD, MBA

Radiation Oncologist

Jeff Michalski

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108
Center for Advanced Medicine

Center for Advanced Medicine

On WashU Medicine Campus
4921 Parkview Place, Saint Louis, MO 63110

Expertise & Training

Clinical Expertise

  • Prostate, kidney and bladder cancer; pediatric cancer; sarcoma; prostate brachytherapy

Primary Academic Title

Carlos A. Perez Distinguished Professor and Vice Chair of Radiation Oncology, WashU Medicine

Board Certification

  • 1991: American Board of Radiology, Radiation Oncology

Training

  • 1986 - 1988: Resident, Internal Medicine and Radiation Oncology, Columbia-Presbyterian Medical Center, New York, NY
  • 1988 - 1990: Resident, Radiation Oncology, WashU Medicine, St. Louis, MO
  • 1990 - 1991: Clinical Instructor/Fellow, Radiation Oncology, WashU Medicine, St. Louis, MO

Education

  • 1986: MD, Medical College of Wisconsin, Milwaukee, WI

Research & Selected Publications

Research Interest

Pediatric radiation oncology, conformal radiotherapy, radiation oncology, quality assurance, genitourinary radiation oncology

Research Publications

An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survival
Authors:

Smith KS, Dhanda SK, Billups CA, one or more additional authors omitted Michalski JM, one or more additional authors omitted Robinson GW

Journal & Year:

Neuro-oncology | 2026

Development and Validation of a Multimodal Artificial Intelligence-derived Digital Pathology-based Biomarker Predicting Metastasis Among Patients with Biochemical Recurrence After …
Authors:

Morgan TM, Ren Y, Tang S, one or more additional authors omitted Michalski JM, one or more additional authors omitted Spratt DE

Journal & Year:

Eur Urol | 2025

Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials
Authors:

Dal Pra A, Ghadjar P, Ryu HM, one or more additional authors omitted Michalski JM, one or more additional authors omitted Zhao SG

Journal & Year:

Ann Oncol | 2025

The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials
Authors:

Nikitas J, Jamshidian P, Tree AC, one or more additional authors omitted Michalski JM, one or more additional authors omitted Kishan AU

Journal & Year:

Lancet Oncol | 2025

Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926
Authors:

Dahl DM, Rodgers JP, Shipley WU, one or more additional authors omitted Michalski JM, one or more additional authors omitted Efstathiou JA

Journal & Year:

J Clin Oncol | 2024

Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial)
Authors:

Kuo PH, Morris MJ, Hesterman J, one or more additional authors omitted Michalski JM, one or more additional authors omitted Herrmann K

Journal & Year:

Radiology | 2024

Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer
Authors:

Lee WR, Dignam JJ, Amin MB, one or more additional authors omitted Michalski JM, one or more additional authors omitted Sandler HM

Journal & Year:

J Clin Oncol | 2024

Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial
Authors:

Buyyounouski MK, Pugh SL, Chen RC, one or more additional authors omitted Michalski JM, one or more additional authors omitted Sandler HM

Journal & Year:

JAMA Oncol | 2024